Equities analysts expect that ADMA Biologics Inc (NASDAQ:ADMA) will announce ($0.55) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for ADMA Biologics’ earnings, with estimates ranging from ($0.70) to ($0.39). ADMA Biologics posted earnings of ($0.35) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 57.1%. The firm is scheduled to issue its next quarterly earnings results on Friday, February 23rd.

According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($2.25) per share for the current year, with EPS estimates ranging from ($2.73) to ($1.66). For the next year, analysts expect that the company will report earnings of ($1.91) per share, with EPS estimates ranging from ($2.25) to ($1.41). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover ADMA Biologics.

ADMA has been the topic of several research analyst reports. Raymond James Financial, Inc. raised shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Tuesday. ValuEngine downgraded shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/15/zacks-brokerages-expect-adma-biologics-inc-adma-to-announce-0-55-eps.html.

In other ADMA Biologics news, insider Adam S. Grossman acquired 485,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The shares were acquired at an average cost of $2.15 per share, with a total value of $1,042,750.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Eric I. Richman acquired 25,000 shares of the company’s stock in a transaction dated Thursday, November 9th. The stock was acquired at an average cost of $2.15 per share, for a total transaction of $53,750.00. Following the completion of the acquisition, the director now directly owns 31,300 shares in the company, valued at $67,295. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 526,500 shares of company stock worth $1,131,975. 60.44% of the stock is owned by insiders.

Shares of ADMA Biologics (ADMA) opened at $2.75 on Wednesday. ADMA Biologics has a 12-month low of $2.01 and a 12-month high of $6.47. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.